SNMMI 2026: Theranostics and Emerging Radiopharmaceuticals Dominate Conference Highlights

At SNMMI 2026, Dr. Jeremie Calais noted rapid expansion of theranostic agents for prostate and neuroendocrine tumors, with growing clinical trial evidence. However, long-term outcomes and broader adoption await further validation.

• Interview with Dr. Calais capturing personal observations from the Society of Nuclear Medicine and Molecular Imaging annual meeting.
• Key themes: new theranostic pairs, alpha-emitter therapies, and artificial intelligence for workflow optimization.
• Limitation: Anecdotal conference highlights; no systematic data synthesis or quantitative analysis.

RadPigeon summaries are original and for information only. They are not clinical advice.